Clinical Data, Comorbidities, and Mortality of COVID-19 in the State of Guanajuato, Mexico until May 20, 2020

Nicolás Padilla-Raygoza¹⁻¹*, Efraín Navarro-Olivos², María de Jesús Gallardo-Luna², Francisco J. Magos-Vázquez², Daniel Alberto Díaz-Martínez², Cuauhtémoc Sandoval-Salazar³, Luis Antonio Díaz-Becerril¹

¹School of Medicine, University of Celaya, Celaya Mexico;
²Institute of Public Health from Guanajuato State, Guanajuato, Mexico;
³Department of Nursing and Obstetrics, Division of Health Sciences and Engineering, University of Guanajuato, Celaya, Mexico

*Corresponding Author

Vol. 9, No. 1 (2020) | ISSN 2166-7403 (online)
DOI 10.5195/cajgh.2020.527 | http://cajgh.pitt.edu

This journal is published by the University Library System of the University of Pittsburgh as part of its D-Scribe Digital Publishing Program and is cosponsored by the University of Pittsburgh Press.
Abstract

Introduction: In December 2019, cases of pneumonia of unknown cause arose in Wuhan, China. The causative agent was subsequently identified as 2019-nCoV and later called SARS-CoV-2. In Mexico, since January 2020 when the first cases were reported, the spread of the infection has occurred throughout the country. The state of Guanajuato, which is located in the center of the country, has taken isolation measures and closed public places in March 2020. The objective of this study was to analyze the evolution, symptoms, co-morbidities and deaths due to confirmed cases of COVID-19.

Methods: An ecological study was designed from the database of confirmed cases of COVID-19 in the state of Guanajuato. Odds ratios and 95% confidence intervals were calculated for symptoms and co-morbidities in deaths of confirmed cases. Logistic regression models were generated adjusting for age group and gender.

Results: Among the 838 confirmed cases in the state, cases with dyspnea and cyanosis showed more significant effect on death. Age group and gender had little involvement as confounders. For practically all comorbidities (including diabetes, hypertension, cardiovascular disease, chronic kidney disease, and immunosuppression), there was a significant effect (odds ratio greater than 2) on mortality from COVID-19. Age group showed a confounding effect on comorbidities and death, but not gender.

Conclusion: The confirmed cases had more than twice the possibility of having comorbidities, compared with those who did not die.

Keywords: SARS-CoV-2; COVID-19; Population; Deaths; Clinical data; Comorbidities

Clinical Data, Comorbidities, and Mortality of COVID-19 in the State of Guanajuato, Mexico, until May 20, 2020

Nicolás Padilla-Raygoza1, Efraín Navarro-Olivos2, María de Jesús Gallardo-Luna2, Francisco J. Magos-Vázquez2, Daniel Alberto Díaz-Martínez2, Cuauhtémoc Sandoval-Salazar3, Luis Antonio Díaz-Becerril1

1School of Medicine, University of Celaya, Celaya Mexico;
2Institute of Public Health from Guanajuato State, Guanajuato, Mexico;
3Department of Nursing and Obstetrics, Division of Health Sciences and Engineering, University of Guanajuato, Celaya, Mexico

Research

At the end of 2019, the World Health Organization (WHO) office in Wuhan, Hubei Province, China, received the report of a case of pneumonia of unknown cause1 that was related to other cases of pneumonia in people who worked or lived near the local Hunan seafood market2-5. The infection spread throughout the city and to other countries and was declared an international public health emergency by the WHO6. The causative agent was determined to be a new coronavirus, called 2019-nCoV and later SARS-CoV-2 by WHO7. It was reported that the cause of COVID-19 shares 79.5% of the SARS-CoV sequence and uses the same cell entry receptor, angiotensin-converting enzyme-2, as SARS-CoV8. Zhu et al.9 reported the cytopathic effects and morphology of the virus and that it is a member of a family of coronaviruses that infect humans. This virus grew more in human airway epithelial cells than tissue culture cells, suggesting the potential for increased infectivity.
COVID-19 patients who present with a comorbid condition may have an increased risk of deterioration and should therefore be admitted to a designated unit for close monitoring in accordance with the WHO guidelines for screening and triage. In a series of 41 patients infected with SARS-CoV-2, 32% had some underlying pathology, 20% had diabetes, 15% had hypertension, 15% had cardiovascular disease, and 2% had chronic obstructive pulmonary disease (COPD). In Mexico, the first detected case started with symptoms on January 8, 2020, and the first two deaths were reported on March 18, 2020. In the state of Guanajuato, before the arrival of the pandemic, the local authorities began measures of social isolation. The closure of educational institutions at all levels began on March 20, 2020, and later, there was the closure of restaurants, gyms, and public parks. Meetings with more than 10 people were also cancelled.

The state of Guanajuato is located in the center of the Mexican Republic (Longitude # 102° 5'49.2" W # 99° 40'16.68" W, Latitude 19° 54'46.08" N 21° 50'21.84" N). As of the 2010 Mexican census, Guanajuato had 5,486,372 inhabitants, accounting for 4.88% of the national population. The state is a relay center for transportation to the four cardinal points of Mexico. In the state of Guanajuato, the first confirmed case of COVID-19 was reported with the onset of symptoms on March 10, 2020, and the first two deaths were reported on April 5, 2020. The number of confirmed cases of COVID-19 in Guanajuato State remained low through April, but given the significant dates in May for the Mexican population, people began to break social isolation, and the number of confirmed cases increased markedly.

The aim of this study was to analyze the effect of clinical data and comorbidities on deaths from COVID-19 in Guanajuato State, Mexico. This is important because few studies are published from Mexico and even less so from Guanajuato State.

Methods

An analytical ecological study was designed with the data reported in the database of the Secretary of Health of the State of Guanajuato, with confirmed cases and deaths from COVID-19 until May 20, 2020. A suspected case is one that manifests fever, cough, dyspnea, and has had a trip abroad to a country with a high frequency of COVID-19 cases or have had contact with a confirmed case. A confirmed case is one that, in addition to the previous criteria, also tested positive for the virus using reverse transcriptase-polymerase chain reaction (RT-PCR).

Sociodemographic variables in the database were age and gender. Among the study variables, the date of onset of symptoms was collected, as well as the clinical data recorded: fever, cough, dyspnea, odynophagia, diarrhea, vomiting, headache, chest pain, cyanosis, abdominal pain, myalgia, arthralgia, and rhinorrhea. All were measured as absent or present. Other variables were comorbidities in the confirmed patient: diabetes, chronic obstructive pulmonary disease (COPD), asthma, immunosuppression, hypertension, cardiovascular disease, chronic kidney disease, obesity, and smoking. The result variable was death and its date. All included registries had a positive RT-PCR test for SARS-CoV-2.

For statistical analysis, descriptive statistics were used to show the variables. Odds ratios (OR) and corresponding 95% confidence intervals (95% CI) were used for clinical data, comorbidities, and COVID-19 death. Logistic regression models were generated between comorbidities and death by COVID-19, using age categories and gender as potential confounding variables. Statistical analyses were performed using STATA 13.0 (Stata Corp., College Station, TX, USA).
Results

The sample consisted of 838 confirmed cases distributed throughout the state, with the municipality of León predominating. The distribution by gender was 378 (45.11%) women and 460 (54.89%) men. Ages ranged from 0 to 93 years, with an average of 45.03 ± 17.76 years.

Figure 1 shows the municipalities of the state of Guanajuato with a report of at least 20 cases; the rest of the municipalities had at least one case reported.

![Map of Guanajuato State](source.png)

Source: INEGI\textsuperscript{14} and SINADEVGE\textsuperscript{15}

Figure 1. Map of Guanajuato State, with municipalities with 20 or more confirmed cases of COVID-19

Figure 2 shows the distribution of confirmed cases of COVID-19 per day. The first detected case in Guanajuato State started with symptoms on March 10, 2020 and the curve remained low, possibly due to the measures of social isolation and closure of public places that began to be applied in the state as of March 17. Throughout April, however, the curve for cases increased. The few confirmed cases in mid-May may be an artifact due to delayed delivery of RT-PCR test results for SARS-CoV-2. Figure 3 shows the distribution of deaths due to COVID-19 per day. The specific mortality rate (SMR=9.55%) for Guanajuato until May 20, 2020 is 80 deaths among 838 cases.
Source: SINAVE/DGE\textsuperscript{15}

**Figure 2.** Distribution of confirmed cases of COVID-19 by day in Guanajuato State, Mexico (n=848)

Source: SINAVE/DGE\textsuperscript{15}

**Figure 3.** Distribution of deaths for COVID-19 by day in Guanajuato State, Mexico (n=80)
Table 1 shows the distribution by age and gender of confirmed cases for COVID-19 by death (n=838). Men accounted for 62.50% of the deaths by COVID-19, though among the non-deceased, accounted for a similar but lower percentage of 54.09%. The OR for gender indicates that being a woman was a protective factor for dying by decreasing the risk by 29%, an effect that is nullified when reviewing the 95% CI. For age group, those aged 60 years or older predominated among the deceased (57.50%).

Presence of dyspnea and cyanosis had the greatest increased risk of death from COVID-19 compared to those who were not deceased. The deceased had more than ten times the odds of having presented dyspnea or cyanosis than those not deceased. Fever and chest pain only had an effect on death four times greater. Diarrhea, cough, vomiting, headache, myalgia, arthralgia, and rhinorrhea had no statistically significant effect on mortality. Sore throat had a protective effect against death. Age group had a confounding effect for dyspnea, chest pain, and cyanosis, but maintained the strong effect of these clinical data on death (Table 2).

Asthma showed a non-significant protective effect. Diabetes, hypertension, COPD, cardiovascular disease, and chronic kidney disease show a strong effect on mortality from COVID-19 with ORs greater than 3. For each of these comorbidities, age group acted as a confounder, decreasing the ORs, but they remained significant. For obesity and smoking, an OR effect was found higher than 2, though age group also acted as a confounder. Gender in no one comorbidities acted as a confounder (Table 3).

| Variable               | Deaths (n=80) | Non-deaths (n=758) | OR (95% CI) |
|------------------------|--------------|-------------------|-------------|
|                        | n            | %     | n     | %     |          |
| Gender                 |              |       |       |       |
| Female                 | 30           | 37.50 | 348   | 45.91 | 0.71 (0.44 to 1.14) |
| Male                   | 50           | 62.50 | 410   | 54.09 |            |
| Age group (years)      |              |       |       |       |
| 0–5                    | 0            | 0     | 14    | 1.85  |            |
| 6–11                   | 0            | 0     | 10    | 1.32  |            |
| 12–19                  | 0            | 0     | 24    | 3.17  |            |
| 20–49                  | 12           | 15.00 | 444   | 58.58 |            |
| 50–59                  | 22           | 27.50 | 145   | 19.13 |            |
| 60 or higher           | 46           | 57.50 | 121   | 15.96 |            |

Source: SINAVE/DGE\textsuperscript{15}

Table 1. Distribution of gender and age group by death for COVID-19 in Guanajuato, Mexico
### Table 2. Distribution of clinical data by death from COVID-19 in Guanajuato, Mexico

| Clinical data     | Confirmed cases (n=838) | Logistic regression OR (95% CI) |
|-------------------|-------------------------|---------------------------------|
|                   | Deaths                  | Non-deaths                      | Unadjusted | Age-adjusted | Gender-adjusted |
|                   | n | %  | n | %  |                  |                   |                  |
| **Fever***         |   |     |   |     |                  |                   |                  |
| Yes               | 74 | 92.50 | 566 | 74.77 | 4.17 (1.78 to 9.72) | 4.19 (1.75 to 10.05) | 4.02 (1.72 to 9.41) |
| No                | 6  | 7.50  | 191 | 25.23 |                   |                   |                  |
| **Cough**         |   |     |   |     |                  |                   |                  |
| Yes               | 72 | 90.00 | 668 | 88.13 | 1.21 (0.57 to 2.60) | 1.18 (0.53 to 2.65) | 1.23 (0.57 to 2.65) |
| No                | 8  | 10.00 | 90  | 11.87 |                   |                   |                  |
| **Sore throat**   |   |     |   |     |                  |                   |                  |
| Yes               | 30 | 37.50 | 466 | 61.48 | 0.37 (0.23 to 0.60) | 0.48 (0.29 to 0.79) | 0.38 (0.24 to 0.61) |
| No                | 50 | 62.50 | 292 | 38.52 |                   |                   |                  |
| **Dyspnea**       |   |     |   |     |                  |                   |                  |
| Yes               | 66 | 82.50 | 152 | 20.05 | 18.80 (10.28 to 34.37) | 11.01 (5.88 to 20.60) | 18.73 (10.23 to 34.36) |
| No                | 14 | 17.50 | 606 | 79.95 |                   |                   |                  |
| **Diarrhea**      |   |     |   |     |                  |                   |                  |
| Yes               | 19 | 23.75 | 96  | 12.66 | 2.15 (1.23 to 3.75) | 1.84 (1.01 to 3.37) | 2.08 (1.19 to 3.64) |
| No                | 61 | 76.25 | 662 | 87.34 |                   |                   |                  |
| **Vomiting**      |   |     |   |     |                  |                   |                  |
| Yes               | 6  | 7.50  | 47  | 6.20  | 1.23 (0.51 to 2.97) | 1.54 (0.60 to 3.98) | 1.22 (0.50 to 2.95) |
| No                | 74 | 92.50 | 711 | 93.80 |                   |                   |                  |
| **Headache**      |   |     |   |     |                  |                   |                  |
| Yes               | 65 | 81.25 | 651 | 85.88 | 0.71 (0.39 to 1.29) | 0.75 (0.39 to 1.44) | 0.72 (0.39 to 1.30) |
| No                | 15 | 18.75 | 107 | 14.12 |                   |                   |                  |
| **Chest pain***   |   |     |   |     |                  |                   |                  |
| Yes               | 40 | 50.00 | 157 | 20.74 | 3.82 (2.38 to 6.13) | 2.61 (1.58 to 4.31) | 3.96 (2.46 to 6.38) |
| No                | 40 | 50.00 | 600 | 79.26 |                   |                   |                  |
| **Abdominal pain**|   |     |   |     |                  |                   |                  |
| Yes               | 9  | 11.25 | 67  | 8.84  | 1.31 (0.63 to 2.73) | 1.04 (0.48 to 2.28) | 1.32 (0.63 to 2.76) |
| No                | 71 | 88.75 | 691 | 91.16 |                   |                   |                  |
| **Myalgias***     |   |     |   |     |                  |                   |                  |
| Yes               | 57 | 71.25 | 521 | 68.82 | 1.12 (0.68 to 1.87) | 1.29 (0.75 to 2.22) | 1.09 (0.66 to 1.82) |
| No                | 23 | 28.75 | 236 | 31.18 |                   |                   |                  |
| **Arthralgias**   |   |     |   |     |                  |                   |                  |
| Yes               | 53 | 66.25 | 441 | 58.18 | 1.41 (0.87 to 2.29) | 1.23 (0.74 to 2.07) | 1.40 (0.86 to 2.27) |
| No                | 27 | 33.75 | 317 | 41.82 |                   |                   |                  |
| **Rhinorrhea**    |   |     |   |     |                  |                   |                  |
| Yes               | 28 | 35.00 | 304 | 40.11 | 0.80 (0.50 to 1.30) | 1.00 (0.60 to 1.68) | 0.82 (0.51 to 1.33) |
| No                | 52 | 65.00 | 454 | 59.89 |                   |                   |                  |
| **Cyanosis****    |   |     |   |     |                  |                   |                  |
| Yes               | 16 | 20.00 | 14  | 1.85  | 13.25 (6.19 to 28.37) | 7.66 (3.34 to 17.53) | 13.81 (6.40 to 29.78) |
| No                | 64 | 80.00 | 742 | 98.15 |                   |                   |                  |

*One case removed for missing information  **Two cases removed for missing information

Source: SINAVE/DGE

This work is licensed under a Creative Commons Attribution 4.0 United States License.
Table 3. Distribution among comorbidities by deaths from COVID-19 in Guanajuato, Mexico

| Comorbidity               | Confirmed cases (n=838) | Logistic regression OR (95% CI) |   |
|---------------------------|-------------------------|-------------------------------|---|
|                           | Deaths                  | Non-deaths                   | Unadjusted | Age-adjusted | Gender-adjusted |
|                           | n           | %         | n        | %         |               |               |               |
| **Diabetes**              |             |           |           |           |               |               |               |
| Yes                       | 25         | 31.25     | 97       | 12.80     | 3.10 (1.84 to 5.22) | 1.29 (0.73 to 2.28) | 3.17 (1.88 to 5.34) |
| No                        | 66         | 68.75     | 661      | 87.20     |               |               |               |
| **Hypertension**          |             |           |           |           |               |               |               |
| Yes                       | 39         | 48.75     | 104      | 13.72     | 5.98 (3.68 to 9.71) | 2.57 (1.50 to 4.40) | 6.01 (3.70 to 9.78) |
| No                        | 41         | 51.25     | 654      | 86.28     |               |               |               |
| **COPD**                  |             |           |           |           |               |               |               |
| Yes                       | 9          | 11.25     | 19       | 2.51      | 4.93 (2.15 to 11.30) | 1.54 (0.64 to 3.69) | 5.06 (2.20 to 11.66) |
| No                        | 71         | 88.75     | 739      | 97.49     |               |               |               |
| **Asthma**                |             |           |           |           |               |               |               |
| Yes                       | 1          | 1.25      | 11       | 1.45      | 0.86 (0.11 to 6.75) | 0.72 (0.08 to 6.33) | 0.85 (0.11 to 6.68) |
| No                        | 79         | 98.75     | 747      | 98.55     |               |               |               |
| **Cardiovascular disease**|             |           |           |           |               |               |               |
| Yes                       | 6          | 7.50      | 15       | 1.98      | 4.01 (1.51 to 10.65) | 1.57 (0.56 to 4.45) | 4.07 (1.53 to 10.85) |
| No                        | 74         | 92.50     | 742      | 98.02     |               |               |               |
| **Immunosuppression**     |             |           |           |           | N/A          | N/A          | N/A          |
| Yes                       | 0          | 0.00      | 9        | 1.19      |               |               |               |
| No                        | 80         | 100.00    | 749      | 98.81     |               |               |               |
| **Chronic kidney disease**|             |           |           |           |               |               |               |
| Yes                       | 3          | 3.75      | 7        | 0.92      | 4.18 (1.06 to 16.49) | 3.19 (0.71 to 14.28) | 4.13 (1.04 to 16.37) |
| No                        | 77         | 96.25     | 751      | 99.08     |               |               |               |
| **Obesity**               |             |           |           |           |               |               |               |
| Yes                       | 24         | 30.00     | 116      | 15.30     | 2.37 (1.41 to 3.98) | 2.19 (1.25 to 3.84) | 2.44 (1.45 to 4.11) |
| No                        | 56         | 70.00     | 642      | 84.70     |               |               |               |
| **Smoking**               |             |           |           |           |               |               |               |
| Yes                       | 13         | 6.25      | 56       | 7.39      | 2.43 (1.27 to 4.67) | 1.76 (0.86 to 3.59) | 2.37 (1.23 to 4.56) |
| No                        | 67         | 83.75     | 702      | 92.61     |               |               |               |

*One case removed for missing information

Source: SINAVE/DGE\textsuperscript{15}

Discussion

The sample of 838 infected with SARS-CoV-2 who developed COVID-19 registered in the state of Guanajuato shows a very slow spread during the month of March, but in April and May, the number of cases increased markedly (Figure 2). This slow spread is possibly due to the initial measures taken by the government of the state for social isolation and closure of public places, as well as the avoidance of massive events. As the quarantine and social isolation continued, the population may have gone out to cover basic needs and obtain food supplies, and in places of supply possibly being infected, infection may have spread. This could explain the increase in cases in the months of April and May despite social isolation. It should not be forgotten that the RT-PCR test only applies to symptomatic patients, so asymptomatic carriers are not detected and may avoid their isolation.

It was reported that after social distancing, 20% of new cases and many hospitalizations could be avoided, but upon completion of isolation, new cases would rebound\textsuperscript{16} and, reinforced by Li et al.\textsuperscript{17}, that the...
imposition of social controls impacts the number of new cases.

The SMR of 9.55% in the state of Guanajuato is slightly lower than that of Mexico, which was 10.59% as of May 15, 2020\textsuperscript{19}, but is higher than the global SMR of 6.34% reported by the WHO\textsuperscript{19}.

The most reported symptoms among the Guanajuato cases were fever, cough, dyspnea, and sore throat, but the symptoms that showed the greatest effect in terms of mortality were cyanosis, dyspnea, and chest pain (Table 2). In a series of 926 symptomatic SARS-CoV-2 infected cases, there was fever reported in 42.2% of cases, cough in 67.2%, dyspnea in 15.0%, arthralgia in 14.4%, headache in 13.4%, sore throat in 14.0%, diarrhea in 3.3%, and vomiting in 4.6%\textsuperscript{20}. The figures reported in patients from Guanajuato, Mexico differ from those described in all of Mexico\textsuperscript{19}. In a series of 44 symptomatic patients with COVID-19, reported fever in 97.7%, cough in 56.8%, dyspnea in 9.1%, and arthralgia in 52.3%. In a series of nine pregnant women, fever was reported in 77.8%, cough in 44.4%, dyspnea in 11.1%, arthralgia in 33.3%, headache in 33.3%, and sore throat in 33.3%\textsuperscript{21}.

The comorbidities with the greatest effect on mortality in patients from the state of Guanajuato are similar (Table 3) to those described in all of Mexico\textsuperscript{19}. In a series of 41 patients infected with SARS-CoV-2 in Wuhan, China, 32% had some underlying pathology, 20% had diabetes, 15% had hypertension, 15% had cardiovascular disease, and 2% had COPD\textsuperscript{22}.

The spread of SARS-CoV-2 infection has been constantly increasing since January 2020. In the state of Guanajuato, since mid-March, the government authorities decided to close educational institutions, mass events, and public places, which resulted in the curve for new confirmed cases remaining low; with community transmission, cases increased dramatically during April and May. The clinical data of the confirmed cases in the state of Guanajuato are similar to those already reported, with cough, fever, and dyspnea as the main symptoms. Mortality in the presence of comorbidities such as diabetes, hypertension, COPD, and cardiovascular disease in the state of Guanajuato are similar to what is reported throughout Mexico. It is important to continue the follow-up of the epidemiology of SARS-CoV-2 in Guanajuato State because it is possible that the number of confirmed cases may rise with the breaking of quarantine.

References

1. World Health Organization. Rolling updates on coronavirus disease (COVID-19). World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen . Updated 7 May 2020. Accessed: June 21, 2020.
2. Lu H, Stratton CW, TangYW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020; 92(4):401-402. Doi: https://doi.org/10.1002/jmv.25678
3. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020; 91: 264-66 Doi: https://doi.org/10.1016/j.ijid.2020.01.009
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223): 497-506 Doi: https://doi.org/10.1016/S0140-6736(20)30183-5
5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet.2020; 395(10223): 507-513 https://doi.org/10.1016/S0140-6736(20)30211-7
6. Yoo JH, Hong ST. The outbreak cases with the novel coronavirus suggest upgraded quarantine and isolation in Korea. J Korean Med Sci. 2020;35(5): e62 Doi: https://doi.org/10.3346/jkms.2020.35.e62
